ライフサイエンスコーパス: e-cigarette

1 r vapers/dual users (Group 2) when using the e-cigarette.

2 e-cigarette users reporting use of flavored e-cigarettes.

3 vestigations of the vehicle solvents used in e-cigarettes.

4 an experimental model following exposure to e-cigarettes.

5 use of drugs other than nicotine (DOTNs) in e-cigarettes.

6 le school students reported exclusive use of e-cigarettes.

7 ter inhalation of aerosol from nicotine-free e-cigarettes.

8 he safety of pure nicotine inhalation, i.e., E-cigarettes.

9 ajor stimulant in tobacco products including e-cigarettes.

10 o successfully quit smoking continued to use e-cigarettes.

11 otherwise healthy humans who habitually use e-cigarettes.

12 PM of conventional cigarettes and the TPM of e-cigarettes.

13 ion, diet, smoking, and more recently, using e-cigarettes.

14 mong 24 healthy dual-users of cigarettes and e-cigarettes.

15 Electronic (e-) cigarette aerosol (particle and gas) is a complex mi

16 a primary 3D airway model acutely exposed to e-cigarette aerosol and cigarette (3R4F) smoke.

17 Two e-cigarette aerosol dilutions were tested for equivalent

18 Days 0, 7, 14-18) and exposed to room air or e-cigarette aerosol for 30 min twice daily, 6 days/week

19 gher nicotine delivery, an acute exposure to e-cigarette aerosol had a reduced impact on gene express

20 Components of e-cigarette aerosol have known pulmonary toxicity.

21 Pulmonary physiology is also affected by e-cigarette aerosol inhalation, with increased airway re

22 ferentially expressed at the highest dose of e-cigarette aerosol using a looser threshold of pFDR < 0

23 hree acids, and one phenolic carbonyl in the e-cigarette aerosol with Classic Tobacco flavor.

24 nts of tobacco smoke have been identified in e-cigarette aerosol, and their involvement in vascular d

25 MRI before and after inhaling nicotine-free e-cigarette aerosol.

26 2 studies reported metal/metalloid levels in e-cigarette aerosols (from cig-a-like and tank devices),

27 E-cigarette aerosols are exceedingly different from conv

28 roxyacetone can be significant components in e-cigarette aerosols but have received less attention in

29 rms of cardiac physiology, acute exposure to e-cigarette aerosols in human subjects led to increased

30 Chronic exposure to e-cigarette aerosols using animal models caused increase

31 or studies on metals/metalloids in e-liquid, e-cigarette aerosols, and biosamples of e-cigarette user

32 24 studies on metals/metalloids in e-liquid, e-cigarette aerosols, and human biosamples of e-cigarett

33 xicology of the complex product formation in e-cigarette aerosols.

34 We hypothesized that nicotine and e-cigarettes affect myofibroblast differentiation, gel c

35 ts of lung injury associated with the use of e-cigarettes (also called vaping) and launched a coordin

36 Ps) and a prototype electronic cigarette (or e-cigarette) among Italian non-mentholated 7 mg ISO tar

37 ding electronic nicotine delivery systems or e-cigarettes) among children and adolescents may help de

38 study was to determine the effect of various e-cigarette and e-liquid modifications, such as coil res

39 Continued monitoring of the prevalence of e-cigarette and other tobacco product use among youth is

40 rrent e-cigarette users; and use of flavored e-cigarettes and flavor types among current exclusive e-

41 tudinal studies that assessed initial use of e-cigarettes and subsequent cigarette smoking.

42 iven the rapid increase in the popularity of e-cigarettes and the paucity of associated longitudinal

43 Unlike cigarette smoking, the effects of e-cigarettes and their constituents on mediating vascula

44 xt words to capture concepts associated with e-cigarettes and traditional cigarettes in articles publ

45 ual users of both combustible cigarettes and e-cigarettes, and long-term users of both combustible ci

46 nerated by conventional cigarettes, EPFRs in e-cigarettes appear to be more potent than those in toba

47 E-cigarettes are a potential source of exposure to metal

48 E-cigarettes are battery-operated devices that heat a li

49 E-cigarettes are commonly used in attempts to stop smoki

50 egral to risk of health effects, but overall e-cigarettes are much less hazardous than cigarettes.

51 nimal studies have identified therefore that e-cigarettes are potentially hazardous, especially in su

52 Flavored e-cigarettes are preferred by the majority of users yet

53 igarettes is harmless, but these claims that e-cigarettes are safer and healthier are not based on ev

54 ic nicotine delivery systems (often known as e-cigarettes) are a novel tobacco product with growing p

55 Electronic cigarettes (e-cigarettes) are an alternate nicotine delivery system

56 Electronic-cigarettes (e-cigarettes) are non-combustible tobacco alternatives t

57 Electronic cigarettes (e-cigarettes) are the preferred smoking-cessation aid in

58 rs who tried to quit with and without use of e-cigarettes as a cessation aid.

59 The current systematic review newly included e-cigarettes as a tobacco product.

60 In conclusion, our data suggest that e-cigarette autofluorescence can be used as a marker of

61 ve recently turned to electronic cigarettes (e-cigarettes) because they have been marketed as a cheap

62 se (>=20 days in the past 30 days) and usual e-cigarette brand among current e-cigarette users; and u

63 school students reported JUUL as their usual e-cigarette brand in the past 30 days; among current e-c

64 school students reported not having a usual e-cigarette brand.

65 ette flavors from the top selling disposable e-cigarette brands.

66 11 (92%) patients reported the use of e-cigarette cartridges containing tetrahydrocannabinol o

67 e consistent in demonstrating that vaping of e-cigarettes causes health effects both similar to and d

68 In parallel, we studied the effects of e-cigarette components on protease secretion in isolated

69 cally, both combustible tobacco products and e-cigarettes contain nicotine, a highly addictive, plant

70 In contrast, all e-cigarettes containing nicotine suppressed airway infla

71 The public health implications of e-cigarettes depend, in part, on whether e-cigarette use

72 hnique, we found that every 70 mL puff of an e-cigarette deposited 0.019% e-liquid (v/v) in a control

73 autofluorescence can be used as a marker of e-cigarette deposition.

74 The role of nicotine and e-cigarette derived nicotine on cellular functions inclu

75 ulmonary exposure to either tobacco smoke or e-cigarettes despite negative respiratory symptoms.

76 , and biosamples of e-cigarette users across e-cigarette device systems to evaluate metal/metalloid e

77 case patients as persons who reported use of e-cigarette devices and related products in the 90 days

78 We assessed whether protonated nicotine and e-cigarette devices delivering greater aerosol mass incr

79 having used tetrahydrocannabinol products in e-cigarette devices, although a wide variety of products

80 rted by 502 (24.0%), of whom 201 (9.6%) used e-cigarettes during the last 30 days (current users).

81 Due to the novelty of e-cigarettes (e-cigs) and e-cigarette liquids (e-liquids

82 g cigarette smokers (CS), individuals vaping e-cigarettes (e-cigs), and non-smokers (NS).

83 E-cigarette (EC) use is increasing exponentially worldwi

84 icotinized electronic cigarettes (hereafter, e-cigarettes) elicit systemic oxidative stress and infla

85 All e-cigarette emissions tested contained at least one alde

86 wever, have found toxic metals/metalloids in e-cigarette emissions.

87 id increase in use of electronic-cigarettes (e-cigarettes), especially among youth, raises the urgenc

88 uences to adult offspring following maternal e-cigarette exposure during pregnancy.

89 Cardiac tissues were collected at the end of e-cigarette exposure for pathological analysis.

90 We found that e-cigarette exposure increased the endothelial cell mark

91 indings support previous adverse findings of e-cigarette exposure on neurodevelopment in a mouse mode

92 In addition, short-term e-cigarette exposure slightly increased collagen content

93 differences in offspring behavior, maternal e-cigarette exposure with nicotine led to a reduction in

94 E-cigarette exposure without nicotine resulted in a 2-fo

95 E-cigarette flavored pods are increasing in use among yo

96 nventional cigarettes, the health effects of e-cigarette flavored pods are unknown.

97 We hypothesized that e-cigarette flavored pods would cause oxidative stress,

98 data provide insights into the regulation of e-cigarette flavored pods, as well as constituents in th

99 his national survey study characterizes JUUL e-cigarette flavors (mint, mango, fruit, and others) mos

100 We selected 24 e-cigarette flavors from the top selling disposable e-ci

101 E-cigarette fluids (with and without nicotine) trigger m

102 HGFs were treated with e-cigarette fluids containing nicotine (final concentrat

103 Electronic cigarettes (e-cigarettes) for smoking cessation remain controversial

104 ritation was reported more frequently in the e-cigarette group (65.3%, vs. 51.2% in the nicotine-repl

105 The e-cigarette group reported greater declines in the incid

106 cipants with 1-year abstinence, those in the e-cigarette group were more likely than those in the nic

107 e-replacement group (37.9%, vs. 31.3% in the e-cigarette group).

108 The 1-year abstinence rate was 18.0% in the e-cigarette group, as compared with 9.9% in the nicotine

109 results suggest that short-term exposure to e-cigarettes has no acute effect on cardiac contractile

110 E-cigarettes have been advertised as a healthy alternati

111 hough many questions regarding the safety of e-cigarettes have come to the forefront with the emergen

112 ectronic nicotine delivery systems (ENDS) or e-cigarettes have emerged as a popular recreational tool

113 E-cigarettes have the ability to deliver nicotine in a m

114 Electronic cigarettes (e-cigarettes) have become popular, in part because they

115 l tobacco cigarettes, electronic cigarettes (e-cigarettes) have been proposed as an effective smoking

116 Electronic cigarettes (e-cigarettes) have experienced a tremendous increase in

117 E-cigarettes heat and aerosolize the solvents propylene

118 There is increasing recognition that e-cigarettes impact vascular function across multiple or

119 Regulations on e-cigarettes in the U.S. do not provide guidelines on th

120 n the short- and long-term health effects of e-cigarettes, including any potential effect on cancer r

121 s imperative to evaluate the health risks of e-cigarettes, including the effects of their ingredients

122 We found that both nicotine and e-cigarette inhibit myofibroblast differentiation as sho

123 Nicotine and e-cigarette inhibited OXPHOS complex III accompanied by

124 Although the production of ROS generated by e-cigarettes is comparatively lower than ROS generated b

125 sers are under the impression that vaping of e-cigarettes is harmless, but these claims that e-cigare

126 Effective nicotine delivery from e-cigarettes is important in consumer acceptance.

127 ols (i.e., vapor plus particulate phases) of e-cigarettes is needed in order to better inform basic r

128 990s, tobacco use via electronic cigarettes (e-cigarettes) is quickly rising and is now more common a

129 otine was also significantly reduced for the e-cigarette (IS1.0(T)) compared to C651.

130 E-cigarettes likely represent a lower risk to health tha

131 electronic nicotine delivery systems (i.e., "e-cigarettes") likely undergo sensitization of cholinerg

132 ed the evidence on metal/metalloid levels in e-cigarette liquid (e-liquid), aerosols, and biosamples

133 y was to investigate the effects of flavored e-cigarette liquids (e-liquids) and serum isolated from

134 to the novelty of e-cigarettes (e-cigs) and e-cigarette liquids (e-liquids), research on their chemo

135 is to further investigate the effects of the e-cigarette liquids (with and without nicotine) on the s

136 rovide guidelines on the chemical content of e-cigarette liquids.

137 This suggests that some flavored e-cigarettes may alter asthma pathophysiology even when

138 A compilation of early data suggest that e-cigarettes may contain numerous toxic substances, incl

139 These results suggest e-cigarettes may not be an effective cessation aid for a

140 Smokers who switch completely to e-cigarettes may reduce their relative risk of tobacco-r

141 Amongst smokers, e-cigarette mean puff volumes (41.6 mL vs 41.3 mL) and m

142 despite no combustion process, the TPM from e-cigarettes (menthol flavor of NJOY and V2 brands) also

143 rapid brain uptake promotes smoking reward, e-cigarettes might maintain a degree of nicotine depende

144 ), nonnicotine e-cigarettes (n = 127), or no e-cigarettes (n = 121) for 12 weeks.

145 nicotine e-cigarettes (n = 128), nonnicotine e-cigarettes (n = 127), or no e-cigarettes (n = 121) for

146 Randomization to nicotine e-cigarettes (n = 128), nonnicotine e-cigarettes (n = 12

147 Self-report of baseline e-cigarette nicotine concentration of none (0 mg/mL), lo

148 needed to determine the long-term effects of e-cigarettes on respiratory health.

149 to smoke generated by electronic cigarettes (e-cigarettes) on-chip.

150 The e-cigarette-only and NRT-only users had significantly lo

151 Former smokers with long-term e-cigarette-only or NRT-only use may obtain roughly simi

152 former smokers with long-term (>/=6 months) e-cigarette-only or NRT-only use, and long-term dual com

153 Long-term NRT-only and e-cigarette-only use, but not dual use of NRTs or e-ciga

154 The e-cigarette-only users had significantly lower NNAL leve

155 se, and long-term dual combustible cigarette-e-cigarette or combustible cigarette-NRT users (n = 36 t

156 arch priorities and prevailing challenges in e-cigarette or vaping product use-associated lung injury

157 using tetrahydrocannabinol (THC)-containing e-cigarette or vaping products; approximately 50% of the

158 The recent outbreak of e-cigarette or vaping-product use-associated lung injury

159 cal Center (Rochester, NY, USA) who had used e-cigarettes or another vaping device in the 30 days bef

160 The widespread use of electronic cigarettes (e-cigarettes or e-cig) is a growing public health concer

161 oking initiation associated with ever use of e-cigarettes or past 30-day cigarette smoking associated

162 oing outbreak of lung injury associated with e-cigarettes or vaping (also known as E-VALI or VALI) st

163 s presented with lung injury associated with e-cigarettes or vaping at 13 hospitals or outpatient cli

164 Lung injury associated with e-cigarettes or vaping is an emerging illness associated

165 ing involving nonsmokers, exclusive users of e-cigarettes or vaping products, and exclusive cigarette

166 Lung injury associated with e-cigarettes or vaping remains a clinical diagnosis with

167 ll patients with lung injury associated with e-cigarettes or vaping seen in Intermountain Healthcare,

168 atients died and lung injury associated with e-cigarettes or vaping was thought to be a contributing

169 nt guideline for lung injury associated with e-cigarettes or vaping.

170 e cigarette-only, dual combustible cigarette-e-cigarette, or dual combustible cigarette-NRT users.

171 ince June, 2019, more than 1000 new cases of e-cigarette, or vaping, product use associated lung inju

172 chemical of concern in the investigation of e-cigarette, or vaping, product use associated lung inju

173 al cases and 60 patients with fatal cases of e-cigarette, or vaping, product use-associated lung inju

174 nence was significantly greater for nicotine e-cigarettes plus counseling vs counseling alone at 12 w

175 g adults motivated to quit smoking, nicotine e-cigarettes plus counseling vs counseling alone signifi

176 Point prevalence abstinence for nonnicotine e-cigarettes plus counseling was not significantly diffe

177 The growing popularity of e-cigarette products has caused an increase in internet

178 e-Cigarette products usually contain nicotine, which is

179 Strong e-cigarette regulation could potentially curb use among

180 LI highlighting the importance of broadening e-cigarette research beyond comparators to smoking-relat

181 uantification of metal/metalloid levels from e-cigarette samples are needed.

182 el, selenium, tin, and zinc, were present in e-cigarette samples in the studies reviewed.

183 Until more is known, e-cigarettes should not be considered a safe alternative

184 inations, provided for up to 3 months, or an e-cigarette starter pack (a second-generation refillable

185 istent findings for nicotine and nonnicotine e-cigarettes, suggesting further research is needed.

186 isk of overdose with DOTNs aerosolized in an e-cigarette system.

187 Among US smokers who used e-cigarettes to help quit, 12.9% (95% confidence interva

188 Prior reports on e-cigarette toxin production have emphasized temperature

189 EPFRs in e-cigarette TPM may be a potential source of health impa

190 ts were asked about their use of cigarettes, e-cigarettes, traditional cigars, cigarillos, filtered c

191 RATIONALE: Rates of adolescent electronic (e-) cigarette use are increasing, but there has been lit

192 of e-cigarettes depend, in part, on whether e-cigarette use affects the risk of cigarette smoking.

193 The prevalence of e-cigarette use among US youth increased from 2011 to 20

194 , which is addictive, raising concerns about e-cigarette use and nicotine addiction in children.

195 ss trends in prevalence of current and daily e-cigarette use by US adults and to characterize trends

196 E-cigarette use continues to rapidly escalate in the USA

197 Self-reported current (past 30-day) e-cigarette use estimates among high school and middle s

198 Acute exposure to flavored e-liquids or e-cigarette use exacerbates endothelial dysfunction, whi

199 In the past 5 years, e-cigarette use has been increasing rapidly, particularl

200 nearly 1500 hospitalizations associated with e-cigarette use have been reported in 49 states and the

201 Pulmonary illnesses related to e-cigarette use have been reported, but no large series

202 years to identify the health consequences of e-cigarette use if we rely only upon human data.

203 ine the long-term cardiopulmonary effects of e-cigarette use in humans.

204 This is concerning given that e-cigarette use is perceived as less harmful than conven

205 neurodevelopmental consequences of maternal e-cigarette use on adult offspring behavior and neuroimm

206 garettes only, former smokers with long-term e-cigarette use only, former smokers with long-term nico

207 In this study, habitual e-cigarette use was associated with a shift in cardiac a

208 e-Cigarette use was associated with greater risk for sub

209 In 2019, the prevalence of self-reported e-cigarette use was high among high school and middle sc

210 Ever e-cigarette use was reported by 502 (24.0%), of whom 201

211 To investigate the associations of e-cigarette use with chronic bronchitis symptoms and whe

212 no statistically significant associations of e-cigarette use with wheeze after adjustment for cigaret

213 equency of combustible cigarette smoking and e-cigarette use within the past 30 days (0 days [none],

214 ookah use, ever e-cigarette use, and current e-cigarette use) among New Jersey high school students,

215 om 38.1% (current hookah use) to 58.3% (ever e-cigarette use), indicating substantial false-negative

216 s (ever hookah use, current hookah use, ever e-cigarette use, and current e-cigarette use) among New

217 lung undergo numerous changes in response to e-cigarette use, and disease development will depend on

218 With the rise of e-cigarette use, teen nicotine exposure is becoming more

219 trials evaluated effects of interventions on e-cigarette use.

220 ee (50%) of whom had relapsed with vaping or e-cigarette use.

221 ) of middle school students reported current e-cigarette use.

222 igarette smoking associated with past 30-day e-cigarette use.

223 esearch indicates that electronic cigarette (e-cigarette) use (vaping) among adolescents is associate

224 Electronic cigarettes (e-cigarettes) use has increased globally and could poten

225 9 self-identified non-tobacco cigarette, non-e-cigarette user control participants.

226 used propensity-score methods to match each e-cigarette user with similar nonusers.

227 was no difference compared with matched non-e-cigarette users (cigarette abstinence difference: 2%;

228 tes and flavor types among current exclusive e-cigarette users (no use of other tobacco products) by

229 n healthy nonsmokers, cigarette smokers, and e-cigarette users (vapers), and determined protease leve

230 quid (e-liquid), aerosols, and biosamples of e-cigarette users across e-cigarette device systems to e

231 study including 23 self-identified habitual e-cigarette users and 19 self-identified non-tobacco cig

232 ollow-up were 21.5% for baseline past 30-day e-cigarette users and 4.6% for baseline non-past 30-day

233 king initiation were 30.4% for baseline ever e-cigarette users and 7.9% for baseline never e-cigarett

234 oss-sectional case-control study of habitual e-cigarette users and nonuser control individuals from 2

235 evaluate metal/metalloid exposure levels for e-cigarette users and the potential implications on heal

236 r past 30-day e-cigarette vs non-past 30-day e-cigarette users at baseline.

237 Otherwise healthy habitual e-cigarette users between the ages of 21 and 45 years me

238 to oxidation, was significantly increased in e-cigarette users compared with nonuser control individu

239 P = .05) were significantly increased in the e-cigarette users compared with nonuser control particip

240 component was significantly decreased in the e-cigarette users compared with nonuser control particip

241 Adolescent e-cigarette users had increased rates of chronic bronchi

242 igarette-NRT, and dual combustible cigarette-e-cigarette users had largely similar levels of TSNA and

243 liquids (e-liquids) and serum isolated from e-cigarette users on endothelial health and endothelial

244 ever, risk of bronchitic symptoms among past e-cigarette users remained elevated after adjustment for

245 nd middle school students, with many current e-cigarette users reporting frequent use and most of the

246 rting frequent use and most of the exclusive e-cigarette users reporting use of flavored e-cigarettes

247 Recent evidence suggests that e-cigarette users tend to change their puffing behaviors

248 Furthermore, fewer e-cigarette users were abstinent from nicotine products

249 eeting these inclusion criteria who were not e-cigarette users were eligible to be enrolled as contro

250 etal/metalloid levels found in biosamples of e-cigarette users were similar or higher than levels fou

251 % CI: -7%, -1%); approximately two-thirds of e-cigarette users who successfully quit smoking continue

252 puffing topography data from 19 experienced e-cigarette users who switched between 18 and 6 mg/mL e-

253 tte brand in the past 30 days; among current e-cigarette users, 13.8% (95% CI, 12.0%-15.9%) of high s

254 Among current e-cigarette users, an estimated 34.2% (95% CI, 31.2%-37.

255 Among current e-cigarette users, an estimated 59.1% (95% CI, 54.8%-63.

256 Among current exclusive e-cigarette users, an estimated 72.2% (95% CI, 69.1%-75.

257 s 3.62 (95% CI, 2.42-5.41) for ever vs never e-cigarette users, and the pooled odds ratio for past 30

258 After exposure of human iPSC-ECs to serum of e-cigarette users, increased ROS linked to endothelial d

259 0-day cigarette smokers who were past 30-day e-cigarette users, past 30-day cigarette smoking at foll

260 ammatory cytokine expression in the serum of e-cigarette users.

261 ng nicotine concentrations and to serum from e-cigarette users.

262 samples (urine, saliva, serum, and blood) of e-cigarette users.

263 -cigarette users and 7.9% for baseline never e-cigarette users.

264 users and 4.6% for baseline non-past 30-day e-cigarette users.

265 uid, e-cigarette aerosols, and biosamples of e-cigarette users.

266 -cigarette aerosols, and human biosamples of e-cigarette users.

267 s) and usual e-cigarette brand among current e-cigarette users; and use of flavored e-cigarettes and

268 The experimental data showed that e-cigarette vaping (3 h/day for 14 days) had no signific

269 E-cigarette vaping also caused slower weight gain compar

270 We subjected C57BL/6 mice to e-cigarette vaping for 2-weeks, and cardiac function was

271 Differences before versus after e-cigarette vaping were tested with Hotelling T(2) test.

272 After e-cigarette vaping, resistivity index was higher (0.03 o

273 The effect of e-cigarettes (vaping) on proteolysis is unknown.

274 in pulmonary injuries associated with using e-cigarette/vaping products.

275 Together, our findings reveal that chronic e-cigarette vapor aberrantly alters the physiology of lu

276 rmaldehyde concentrations of 626 mug/m(3) in e-cigarette vapor exceed the ACGIH maximum concentration

277 ions of aldehydes and flavoring chemicals in e-cigarette vapor under typical usage conditions.

278 most prevalent of the flavoring chemicals in e-cigarette vapor, being found in more than 60% of sampl

279 tion as a pathway for aldehyde generation in e-cigarette vapors.

280 comparison of evidence regarding the role of e-cigarettes versus combustible tobacco in vascular dise

281 was 4.28 (95% CI, 2.52-7.27) for past 30-day e-cigarette vs non-past 30-day e-cigarette users at base

282 pharmacokinetics and product liking for two e-cigarettes (Vype ePen3 and Vype ePen) with various nic

283 The radical concentration in e-cigarettes was much lower as compared to tobacco TPM.

284 d multiple tobacco products; cigarettes plus e-cigarettes was the most common combination.

285 E-cigarettes were connected to a pump drawing air for tw

286 E-cigarettes were more effective for smoking cessation t

287 It is highly likely that chronic use of e-cigarettes will induce pathological changes in both th

288 ette with counseling: 120 [94%]; nonnicotine e-cigarette with counseling: 118 [93%]; counseling only:

289 Adverse events were common (nicotine e-cigarette with counseling: 120 [94%]; nonnicotine e-ci

290 starter pack (a second-generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg

291 Associations of self-reported use of e-cigarettes with chronic bronchitic symptoms (chronic c

292 arette-only use, but not dual use of NRTs or e-cigarettes with combustible cigarettes, is associated

293 Use of e-cigarettes with high (vs no) nicotine concentration wa

294 udy provide preliminary evidence that use of e-cigarettes with higher nicotine concentrations by yout

295 To evaluate whether use of e-cigarettes with higher nicotine concentrations is asso

296 otine delivery systems (ENDS), also known as e-cigarettes, with a variety of e-liquids/e-juices, is i

297 .4%) of middle school students used flavored e-cigarettes, with fruit, menthol or mint, and candy, de

298 to determine the effect of selected flavored e-cigarettes, with or without nicotine, on allergic airw

299 w-up) of 2015 to students who reported using e-cigarettes within the past 30 days and the nicotine co

300 Flavored e-cigarettes without nicotine had significant but hetero